Levels of HDAC2 and SGRQ-C in C and D Grup COPD Patients with Inhaled ICS/LABA and History of Smoking

· Biomolecular, COPD

Triwahju Astuti, Ungky Agus Setyawan, Sri Handayani Rahayu
Departemen Pulmonologi dan Kedokteran Respirasi Fakultas Kedokteran Universitas Brawijaya, Malang

Background: In chronic obstructive pulmonary disease (COPD,) especially in smoker patients, there is a reduction in histone deacetylase-2 (HDAC2) activity and expression which is caused by oxidative stress. It’s linked with corticosteroids resistance. GOLD recommendation therapy for C and D groupCOPD is combination of long-acting beta-2 agonist and corticosteroids (LABACS). The association between levels of HDAC2 serum in COPD patients with smoking history and efficacy of LABACS has not established yet.This study was aimed to determine levels of HDAC2 serum in these patients and its relationship with the quality of life (QoL).
Methods: Cross sectional analytic study. 36 C and D population COPD patients in Saiful Anwar General Hospital Malang Indonesia were grouped into LABACS and no-LABACS. Expression HDAC2 serum _was assessed using Elisa and QoL was assessed using St George’s Respiratory Questionnaire (SGRQ-C).
Results: There was no significant difference in HDAC2 serum between these groups (p=0.628). There was no significant difference in score of SGRQ-C too (p=0.476). There wasaweak correlation between the levels of HDAC2 serum and SGRQ-C score (r=0.227, p=0.183) but not significant.
Conclusion: There was no difference in HDAC2 serum expression and SGRQ-C score in LABACS and no-LABACS group. There was no correlation between HDAC2 serum expression and SGRQ-C score. (J Respir Indo. 2017; 37: 241-8)


Download article here